Journal article
The aspirin in reducing events in the elderly trial: Statistical analysis plan
Rory Wolfe, Anne M Murray, Robyn L Woods, Brenda Kirpach, David Gilbertson, Raj C Shah, Mark R Nelson, Christopher M Reid, Michael E Ernst, Jessica Lockery, Geoffrey A Donnan, Jeff Williamson, John J McNeil
International Journal of Stroke | SAGE PUBLICATIONS LTD | Published : 2018
Abstract
Rationale Aspirin has positive and negative effects on a number of age-related chronic conditions and there is uncertainty regarding its role in primary prevention in people aged 70 years and over. Aims To assess whether daily active treatment of 100 mg enteric-coated aspirin will extend the duration of disability-free life in healthy older participants. Design A double-blind, randomized, placebo-controlled primary prevention trial undertaken in Australia and the United States with careful adjudication of endpoints including stroke. Study outcome In Australia 16,703 individuals were recruited through general practices across five states and territories, and in the United States, 2411 partici..
View full abstractGrants
Awarded by National Institute on Aging at the National Institutes of Health
Awarded by National Cancer Institute at the National Institutes of Health
Awarded by National Health and Medical Research Council of Australia
Awarded by NATIONAL INSTITUTE ON AGING
Funding Acknowledgements
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the National Institute on Aging and the National Cancer Institute at the National Institutes of Health (grant number U01AG029824); the National Health and Medical Research Council of Australia (grant numbers 334047 and 1127060); Monash University (Australia); and the Victorian Cancer Agency (Australia).